Host Defense® CordyChi®: The Pharmacist's Guide to Cordyceps & Reishi Synergy

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

The Clinical Question

What does peer-reviewed human evidence establish for Cordyceps militaris and Reishi (Ganoderma lucidum) individually and in combination — and does the evidence support the biological rationale for combining them in a product like Host Defense® CordyChi®?

Bottom Line Up Front

Both Cordyceps militaris and Reishi have been studied in human randomized trials. The evidence varies substantially by outcome:

• C. militaris immune markers — LIMITED / SUPPORTIVE: two independent RCTs report changes in NK-cell activity and selected cell-mediated immune parameters; samples are small, preparations differ, and results do not establish protection against illness.
• Reishi immune markers — LIMITED / SUPPORTIVE: one double-blind RCT of purified Reishi-derived β-glucan reports changes in T-cell subsets and NK-cell parameters; clinical significance of biomarker changes is unclear.
• Reishi fatigue & well-being — LIMITED / SUPPORTIVE: one double-blind RCT in neurasthenia patients reported improvements in fatigue measures; not established for anxiety, sleep, or HPA-axis effects.
• Reishi as cancer adjunct — LIMITED / LOW-CERTAINTY: Cochrane review found generally poor-quality studies; evidence insufficient to support Reishi as a cancer treatment.
• Reishi cardiovascular & metabolic effects — NOT ESTABLISHED: Cochrane review (5 trials, 398 participants) and a 2025 GRADE-assessed meta-analysis (17 RCTs, 971 participants) did not establish clinically meaningful benefit; the 2025 analysis found modest changes in a few selected outcomes at very-low-certainty GRADE evidence.
• Cordyceps + Reishi clinical synergy — NOT ESTABLISHED: two human combination trials showed null metabolic/cardiovascular and null cognitive outcomes.
• CordyChi® finished-product efficacy — NOT ESTABLISHED: no independent clinical trial has tested this specific product.

What Human Studies Show

1. Cordyceps militaris — Immune Markers — LIMITED / SUPPORTIVE

• HUMAN RCT Kang et al., 2015 (PMID: 26284906) — C. militaris, n=79, 4 weeks: Randomized controlled trial in 79 healthy Korean men; C. militaris 1.5 g/day for 4 weeks. Reported increases in NK-cell activity, lymphocyte proliferation, IL-2, and IFN-γ. No significant adverse reactions. This is the strongest available human evidence that a specific C. militaris preparation can influence NK-cell activity and selected cell-mediated immune markers in healthy adults. It does not establish protection against infection or illness.
• HUMAN RCT Ontawong et al., 2024 (PMID: 38580687) — C. militaris beverage, 8 weeks: Randomized controlled clinical trial; participants received a fermented C. militaris beverage containing 2.85 mg cordycepin for 8 weeks. Small sample (approximately n=10 per sex group); reported NK-cell changes in certain sex/time comparisons and reductions from baseline in selected inflammatory cytokines. Safety indices did not differ between groups. Limitation: small per-group sample size and sex-stratified NK findings limit generalizability.

2. Reishi (Ganoderma lucidum) — Immune Markers — LIMITED / SUPPORTIVE

• HUMAN RCT Chen et al., 2023 (PMID: 36766186) — Reishi β-glucan, double-blind RCT: Randomized, double-blind, placebo-controlled trial in healthy adult volunteers. Purified Reishi-derived β-1,3;1,6 D-glucan was associated with changes in CD3+, CD4+, CD8+ T-cell subsets, CD4/CD8 ratio, NK-cell counts, NK-cell cytotoxicity, and serum IgA. Well tolerated; no significant changes in liver or kidney markers. Evidence supports that a specific Reishi-derived β-glucan preparation may modulate selected innate and adaptive immune parameters in healthy adults. The clinical significance of these biomarker changes is not established, and this trial does not support claims of benefit in autoimmune disease. Note: tested a purified β-glucan isolate, not whole Reishi or CordyChi®.

3. Reishi — Fatigue & Well-Being — LIMITED / SUPPORTIVE

• HUMAN RCT Tang et al., 2005 (PMID: 15857210) — Reishi polysaccharide, n=132, 8 weeks: Randomized, double-blind, placebo-controlled study in 132 patients with neurasthenia (123 evaluable); Ganoderma polysaccharide extract vs. placebo for 8 weeks. Reported improvements in fatigue and well-being measures. Limitation: conducted in a specific clinical population (neurasthenia); results should not be extrapolated to anxiety reduction, sleep quality improvement, GABA receptor activity, or HPA-axis normalization, which were not outcomes in this trial.

4. Reishi as Cancer Adjunct — LIMITED / LOW-CERTAINTY

• CRITICAL APPRAISAL Jin et al., 2016 (PMID: 27045603) — Cochrane systematic review, Reishi + cancer: Cochrane systematic review of Ganoderma lucidum as an adjunct to conventional cancer therapy. Found some evidence of changes in selected immune parameters (CD3/CD4/CD8, marginal NK-cell activity increases) when used alongside conventional treatment. However, the underlying studies had generally unsatisfactory methodological quality, and G. lucidum alone did not demonstrate comparable tumor regression. The review concluded that evidence is insufficient to establish Reishi as an effective cancer treatment. Reishi should not replace established oncologic therapy.

5. Reishi — Cardiovascular & Metabolic Outcomes — NOT ESTABLISHED

• CRITICAL APPRAISAL Klupp et al., 2015 (PMID: 25686270) — Cochrane review, cardiovascular risk factors, 5 trials, 398 participants: Cochrane systematic review of G. lucidum for cardiovascular risk factors. Five controlled trials (398 participants) met eligibility criteria. The review found no significant improvements in HbA1c, total cholesterol, LDL, BMI, fasting glucose, blood pressure, or triglycerides. Authors concluded that evidence did not support G. lucidum for treatment of cardiovascular risk factors.
• CRITICAL APPRAISAL PMID: 40510787 — 2025 GRADE-assessed meta-analysis, 17 RCTs, 971 participants: Pooled analysis of 17 RCTs (971 participants). Found modest statistically significant changes in a few selected outcomes (including BMI, creatinine, GPx, and heart rate), but no significant overall effect on blood pressure, lipid profile, fasting glucose, inflammatory markers, or liver enzymes. GRADE certainty of evidence was rated as very low across outcomes, limiting the clinical interpretability of any positive signals. This is the most comprehensive current human evidence summary for Reishi clinical effects.

6. Why Cordyceps and Reishi Are Combined — Biological Rationale vs. Clinical Evidence

Cordyceps militaris and Reishi contain different primary bioactive compounds — cordycepin and adenosine (Cordyceps) vs. β-glucan polysaccharides and triterpenoids (Reishi) — and have been independently studied for immune and other physiological effects in humans. This provides a biological rationale for combining them. However, evidence that the combination produces synergistic clinical effects greater than either mushroom alone has not been established in well-controlled human trials.

• CRITICAL APPRAISAL PMID: 27511742 — Ganoderma + Cordyceps combination, double-blind RCT, 16 weeks: Double-blind, randomized, placebo-controlled trial; 84 participants with type 2 diabetes/metabolic syndrome randomized to G. lucidum, G. lucidum + Cordyceps sinensis, or placebo for 16 weeks. The combination did not improve primary or secondary metabolic or cardiovascular outcomes. Note: used C. sinensis, not C. militaris; findings are not directly transferable to CordyChi®, but directly challenge assumptions of automatic cardiovascular synergy from combining these species.
• CRITICAL APPRAISAL PMID: 29199566 — Ophiocordyceps sinensis + Ganoderma lucidum, cognition RCT, n=96: Randomized trial of 96 healthy adults; high-dose combination, low-dose combination, or placebo for 30 days. The combination did not significantly improve global cognition, memory, executive function, attention, processing speed, visuospatial function, verbal function, or motor skills. Note: used C. sinensis and evaluated cognition, not immunity; not directly transferable to CordyChi®, but represents the only available human evidence for this specific species combination and showed a null result.

Known Limitations in the Evidence Base

• C. militaris immune RCTs are small and use different preparations; neither measured clinical illness outcomes such as infection rates
• Reishi immune RCT (PMID: 36766186) used a purified β-glucan isolate, not whole Reishi; does not support use in autoimmune disease
• Reishi fatigue evidence (PMID: 15857210) is in neurasthenia patients and cannot be extrapolated to anxiety, sleep quality, GABA activity, or HPA-axis effects
• Cochrane review (PMID: 27045603) found generally poor-quality oncology studies; Reishi should not replace conventional cancer therapy
• A Cochrane review and a 2025 GRADE-assessed meta-analysis did not establish clinically meaningful cardiovascular or metabolic benefit from Reishi; the 2025 analysis found modest changes in selected outcomes, but certainty was very low
• Both available human combination trials (PMIDs 27511742 and 29199566) showed null results; both used C. sinensis, not C. militaris
• No independent clinical trial has tested Host Defense® CordyChi® as a finished product
• Preclinical evidence (in vitro, animal) for ATP synthesis, Nrf2 activation, GABA modulation, platelet effects, and ACE inhibition is not equivalent to demonstrated human clinical efficacy

Safety & Drug Interactions

• Anticoagulants and antiplatelet agents: Reishi has demonstrated antiplatelet activity in preclinical research. Use with caution if taking warfarin, aspirin, clopidogrel, or other anticoagulants. Consult your Khang Pharmacy pharmacist before use.
• Immunosuppressive medications: Specific Cordyceps and Reishi preparations have altered immune biomarkers in human trials. Patients on immunosuppressive medications (transplant, autoimmune disease management) should consult their prescriber and pharmacist before use.
• Autoimmune conditions: Immune-modulating effects observed in healthy adult trials have unknown implications in autoimmune disease. Autoimmune conditions are a reason to seek pharmacist or physician guidance before use, not a target indication.
• Diabetes and blood glucose medications: While human trials have not demonstrated significant glucose-lowering effects, patients on glucose-lowering medications should monitor as a precaution.
• Generally well tolerated: Both RCT series reported no significant adverse effects at study doses. Long-term safety data are limited.

About Host Defense® CordyChi®

Host Defense® CordyChi® Capsules combine certified organic Cordyceps militaris and Ganoderma lucidum (Reishi) mycelium grown on organic brown rice. The product is described by the manufacturer as non-GMO, vegan, and gluten-free. The suggested use is 2 capsules once daily. Host Defense tests products for identity, composition, purity, and strength, and reports that capsule products contain >55% polysaccharides; individual compound concentrations such as cordycepin or specific triterpenoids are not separately quantified or guaranteed for this product.

Who Might Consider CordyChi®?

Based on the available human evidence, CordyChi® may be a reasonable consideration for:

• Adults seeking a dual-mushroom formula with published C. militaris and Reishi human immunology data
• Those interested in adaptogenic mushroom supplementation alongside — not instead of — established wellness practices
• Patients who prefer a certified organic, non-GMO, vegan formula with documented polysaccharide content

CordyChi® is not recommended as a primary treatment for cardiovascular disease, cancer, autoimmune disease, sleep disorders, or anxiety. The clinical evidence does not support these applications in the current literature.

Pharmacist’s Interpretation

As a PharmD, I discuss CordyChi® with patients who are interested in mushroom-based immune support within a realistic evidence framework. Cordyceps militaris and Reishi individually have human RCT data showing effects on immune biomarkers and, for Reishi, fatigue measures. These are meaningful signals, not proof of clinical disease prevention or treatment.

The cardiovascular, sleep, anxiety, and cancer claims commonly associated with these mushrooms are either not supported or actively contradicted by the best available human evidence — including two Cochrane reviews and a 2025 GRADE-assessed meta-analysis. I do not present CordyChi® as clinically proven for these outcomes.

The biological rationale for combining Cordyceps and Reishi is plausible based on their distinct bioactive profiles. Clinical synergy has not been established in human trials. The two available combination trials both showed null results, which I disclose transparently.

Call us at (408) 622-8068 for a free pharmacist consultation before starting any new supplement, particularly if you manage a cardiovascular, autoimmune, or oncologic condition.

Frequently Asked Questions

Q: Does CordyChi® boost the immune system?
A: Specific C. militaris and Reishi preparations have altered immune biomarkers in human RCTs. These are biomarker changes in small trials, not demonstrated protection against infection or illness. No trial has tested CordyChi® as a finished product for immune outcomes.

Q: Can CordyChi® help with energy or fatigue?
A: One double-blind RCT in neurasthenia patients (PMID: 15857210) reported fatigue improvements with a Reishi polysaccharide extract. This is limited evidence in a specific clinical population and cannot be directly applied to CordyChi®.

Q: Is there evidence for the Cordyceps + Reishi combination specifically?
A: Two human RCTs have tested Cordyceps + Reishi combinations. Both found null results — one for metabolic/cardiovascular outcomes (PMID: 27511742), one for cognition (PMID: 29199566). Both used C. sinensis, not C. militaris. Clinical synergy from combining these species has not been established.

Q: Does Reishi support cardiovascular health?
A: A Cochrane review (PMID: 25686270) and a 2025 GRADE-assessed meta-analysis (PMID: 40510787) did not establish clinically meaningful cardiovascular or metabolic benefit. The 2025 analysis found modest changes in a few selected outcomes, but certainty was very low. Preclinical evidence exists but does not translate to established human clinical effects.

Q: Is CordyChi® safe with my medications?
A: If you take anticoagulants, antiplatelet agents, immunosuppressants, or glucose-lowering medications, consult your Khang Pharmacy pharmacist before starting CordyChi®. Reishi has preclinical antiplatelet activity and specific Cordyceps and Reishi preparations have altered immune markers in human trials.

Q: Can Reishi help with cancer?
A: A Cochrane systematic review (PMID: 27045603) found generally poor-quality studies with some immune-marker changes when Reishi was used alongside conventional therapy. Evidence is insufficient to support Reishi as a cancer treatment. It should not replace established oncologic care. Discuss with your oncologist before use.

Selected Key Studies

1. HUMAN RCT Kang HJ, et al. Cordyceps militaris Enhances Cell-Mediated Immunity in Healthy Korean Men. J Med Food. 2015. PMID: 26284906.
   n=79; 1.5 g/day, 4 weeks; increased NK-cell activity, lymphocyte proliferation, IL-2, IFN-γ; no significant adverse effects.
2. HUMAN RCT Ontawong A, et al. A randomized controlled clinical trial examining the effects of Cordyceps militaris beverage on the immune response in healthy adults. Sci Rep. 2024. PMID: 38580687.
   Fermented C. militaris beverage, 2.85 mg cordycepin, 8 weeks; ~n=10/sex group; NK-cell changes in sex/time comparisons; safe profile. Small sample limits generalizability.
3. HUMAN RCT Chen SN, et al. Evaluation of Immune Modulation by β-1,3;1,6 D-Glucan Derived from Ganoderma lucidum in Healthy Adult Volunteers, A Randomized Controlled Trial. Foods. 2023. PMID: 36766186.
   Double-blind RCT; purified Reishi β-glucan; changes in CD3+, CD4+, CD8+, CD4/CD8, NK-cell counts/cytotoxicity, IgA; well tolerated. Tested β-glucan isolate, not whole Reishi.
4. HUMAN RCT Tang W, et al. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. J Med Food. 2005;8:53–58. PMID: 15857210.
   n=132 (123 evaluable); Reishi polysaccharide vs. placebo; 8 weeks; improved fatigue and well-being. Population: neurasthenia patients.
5. CRITICAL APPRAISAL Jin X, et al. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2016. PMID: 27045603.
   Cochrane SR; generally poor-quality studies; some immune-marker changes adjunctive to chemo/radiation; evidence insufficient for cancer treatment; does not replace oncologic care.
6. CRITICAL APPRAISAL Klupp NL, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 2015. PMID: 25686270.
   5 controlled trials, 398 participants; no significant improvement in HbA1c, cholesterol, LDL, BMI, glucose, blood pressure, or triglycerides.
7. CRITICAL APPRAISAL The Nutritional Significance of Ganoderma lucidum on Human Health: A GRADE-Assessed Systematic Review and Meta-Analysis of Clinical Trials. 2025. PMID: 40510787.
   17 RCTs, 971 participants; modest changes in selected outcomes (BMI, creatinine, GPx, heart rate); no significant overall effect on blood pressure, lipids, glucose, inflammation, or liver enzymes; GRADE certainty: very low across outcomes.
8. CRITICAL APPRAISAL A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. PMID: 27511742.
   n=84; G. lucidum, G. lucidum + C. sinensis, or placebo; 16 weeks; combination did not improve metabolic/cardiovascular primary or secondary outcomes.
9. CRITICAL APPRAISAL Clinical Effects of a Commercial Supplement of Ophiocordyceps sinensis and Ganoderma lucidum on Cognitive Function of Healthy Young Volunteers. PMID: 29199566.
   n=96; high-dose, low-dose, or placebo; 30 days; no significant improvement in any cognitive domain tested.

Reviewed by:

Dai Tran, PharmD, MBA, B.S. • View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com